# Reduction in the Occurrence of Center-Involved Diabetic Macular Edema

> **NCT00090519** · PHASE3 · COMPLETED · sponsor: **Chromaderm, Inc.** · enrollment: 731 (actual)

## Conditions studied

- Diabetic Retinopathy

## Interventions

- **DRUG:** ruboxistaurin
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00090519
- **Lead sponsor:** Chromaderm, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 731 (ACTUAL)
- **Last updated:** 2016-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00090519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00090519, "Reduction in the Occurrence of Center-Involved Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00090519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*